U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Thymic neuroendocrine carcinoma

MedGen UID:
900590
•Concept ID:
C2210965
•
Neoplastic Process
Synonyms: Neuroendocrine carcinoma of thymus; neuroendocrine carcinoma of thymus; Thymic Neuroendocrine Carcinoma; thymic neuroendocrine carcinoma; thymus neuroendocrine carcinoma
SNOMED CT: Neuroendocrine carcinoma of thymus (716653001); Thymic neuroendocrine carcinoma (716653001)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
•Concept ID:
CN307044
•
Finding
Source: Orphanet
clinical entity without genetic inheritance.
See: This record
Not genetically inherited (Orphanet)
 
Monarch Initiative: MONDO:0020516
Orphanet: ORPHA99869

Definition

Thymic neuroendocrine carcinoma is a type of thymic epithelial neoplasm displaying evidence of neuroendocrine differentiation. The exact prevalence or incidence is unknown. Men are predominantly affected. Thymic neuroendocrine carcinoma is aggressive with a poor prognosis. [from SNOMEDCT_US]

Professional guidelines

PubMed

The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study.
Miyata R, Hamaji M, Omasa M, Miyahara S, Aoyama A, Takahashi Y, Sumitomo R, Huang CL, Hijiya K, Nakagawa T, Yokoyama Y, Kawakami K, Sonobe M, Ikeda M, Fujinaga T, Suga M, Hirota S, Kojima F, Bando T, Takahashi M, Terada Y, Shoji T, Katakura H, Muranishi Y, Miyahara R, Date H
Surg Today 2021 Apr;51(4):502-510. Epub 2020 Aug 10 doi: 10.1007/s00595-020-02102-7. PMID: 32776294

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023

Recent clinical studies

Etiology

Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas.
Hamaji M, Omasa M, Nakanishi T, Nakakura A, Morita S, Miyamoto E, Nakagawa T, Miyahara S, Sonobe M, Takahashi M, Terada Y, Hijiya K, Sumitomo R, Huang CL, Kojima F, Shoji T, Date N, Miyata R, Suga M, Nakanobo R, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2021 Jul 26;33(2):242-249. doi: 10.1093/icvts/ivab079. PMID: 34151358Free PMC Article
The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study.
Miyata R, Hamaji M, Omasa M, Miyahara S, Aoyama A, Takahashi Y, Sumitomo R, Huang CL, Hijiya K, Nakagawa T, Yokoyama Y, Kawakami K, Sonobe M, Ikeda M, Fujinaga T, Suga M, Hirota S, Kojima F, Bando T, Takahashi M, Terada Y, Shoji T, Katakura H, Muranishi Y, Miyahara R, Date H
Surg Today 2021 Apr;51(4):502-510. Epub 2020 Aug 10 doi: 10.1007/s00595-020-02102-7. PMID: 32776294
Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma.
Hamaji M, Omasa M, Nakagawa T, Miyahara S, Suga M, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2020 Jul 1;31(1):98-101. doi: 10.1093/icvts/ivaa059. PMID: 32386314
Low incidence of and mortality from a second malignancy after resection of thymic carcinoma†.
Hamaji M, Kawaguchi A, Omasa M, Nakagawa T, Sumitomo R, Huang CL, Fujinaga T, Ikeda M, Shoji T, Katakura H, Motoyama H, Menju T, Aoyama A, Sato T, Chen-Yoshikawa TF, Sonobe M, Date H
Interact Cardiovasc Thorac Surg 2019 Mar 1;28(3):375-379. doi: 10.1093/icvts/ivy260. PMID: 30137401
Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin: A comparative study with their pulmonary counterparts.
Bi Y, Deng Y, Li S, Zhou X, Chen Y, Ma D, Mao X, Guan Y, Chen J, Meng Y
J Surg Oncol 2016 Nov;114(6):697-702. Epub 2016 Oct 20 doi: 10.1002/jso.24393. PMID: 27761900

Diagnosis

Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas.
Hamaji M, Omasa M, Nakanishi T, Nakakura A, Morita S, Miyamoto E, Nakagawa T, Miyahara S, Sonobe M, Takahashi M, Terada Y, Hijiya K, Sumitomo R, Huang CL, Kojima F, Shoji T, Date N, Miyata R, Suga M, Nakanobo R, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2021 Jul 26;33(2):242-249. doi: 10.1093/icvts/ivab079. PMID: 34151358Free PMC Article
Neuroendocrine Tumors of the Thyroid and Their Mimics.
Livolsi VA
Endocr Pathol 2021 Jun;32(2):211-221. Epub 2021 Mar 9 doi: 10.1007/s12022-021-09672-3. PMID: 33687689
Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma.
Hamaji M, Omasa M, Nakagawa T, Miyahara S, Suga M, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2020 Jul 1;31(1):98-101. doi: 10.1093/icvts/ivaa059. PMID: 32386314
Low incidence of and mortality from a second malignancy after resection of thymic carcinoma†.
Hamaji M, Kawaguchi A, Omasa M, Nakagawa T, Sumitomo R, Huang CL, Fujinaga T, Ikeda M, Shoji T, Katakura H, Motoyama H, Menju T, Aoyama A, Sato T, Chen-Yoshikawa TF, Sonobe M, Date H
Interact Cardiovasc Thorac Surg 2019 Mar 1;28(3):375-379. doi: 10.1093/icvts/ivy260. PMID: 30137401
Adrenocorticotropic hormone-producing thymic neuroendocrine carcinoma with oncocytic features: a case report and review of literature.
Falk NK, Weissferdt A, Habra MA, Roy-Chowdhuri S
Diagn Cytopathol 2015 Apr;43(4):329-34. Epub 2014 Oct 30 doi: 10.1002/dc.23209. PMID: 25354884

Therapy

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN
JCO Precis Oncol 2024 Nov;8:e2400328. Epub 2024 Nov 7 doi: 10.1200/PO.24.00328. PMID: 39509670
The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study.
Miyata R, Hamaji M, Omasa M, Miyahara S, Aoyama A, Takahashi Y, Sumitomo R, Huang CL, Hijiya K, Nakagawa T, Yokoyama Y, Kawakami K, Sonobe M, Ikeda M, Fujinaga T, Suga M, Hirota S, Kojima F, Bando T, Takahashi M, Terada Y, Shoji T, Katakura H, Muranishi Y, Miyahara R, Date H
Surg Today 2021 Apr;51(4):502-510. Epub 2020 Aug 10 doi: 10.1007/s00595-020-02102-7. PMID: 32776294
A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors.
Mascarenhas L, Malogolowkin M, Armenian SH, Sposto R, Venkatramani R
Pediatr Blood Cancer 2013 Jul;60(7):1103-7. Epub 2013 Jan 17 doi: 10.1002/pbc.24471. PMID: 23335436Free PMC Article
Thymic neuroendocrine carcinoma presenting as cushing's syndrome: treatment with octreotide combined with surgery and radiotherapy.
Asicioglu E, Gonenli G, Kahveci A, Yildizeli B, Deyneli O, Yavuz D, Yuksel M, Akalin S
Onkologie 2011;34(1-2):46-9. Epub 2011 Jan 17 doi: 10.1159/000323348. PMID: 21346385
Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature.
Filosso PL, Actis Dato GM, Ruffini E, Bretti S, Ozzello F, Mancuso M
J Thorac Cardiovasc Surg 2004 Apr;127(4):1215-9. doi: 10.1016/j.jtcvs.2003.09.058. PMID: 15052231

Prognosis

The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study.
Miyata R, Hamaji M, Omasa M, Miyahara S, Aoyama A, Takahashi Y, Sumitomo R, Huang CL, Hijiya K, Nakagawa T, Yokoyama Y, Kawakami K, Sonobe M, Ikeda M, Fujinaga T, Suga M, Hirota S, Kojima F, Bando T, Takahashi M, Terada Y, Shoji T, Katakura H, Muranishi Y, Miyahara R, Date H
Surg Today 2021 Apr;51(4):502-510. Epub 2020 Aug 10 doi: 10.1007/s00595-020-02102-7. PMID: 32776294
Survival outcomes of patients with high-grade and poorly differentiated thymic neuroendocrine carcinoma.
Hamaji M, Omasa M, Nakagawa T, Miyahara S, Suga M, Kawakami K, Aoyama A, Date H
Interact Cardiovasc Thorac Surg 2020 Jul 1;31(1):98-101. doi: 10.1093/icvts/ivaa059. PMID: 32386314
Low incidence of and mortality from a second malignancy after resection of thymic carcinoma†.
Hamaji M, Kawaguchi A, Omasa M, Nakagawa T, Sumitomo R, Huang CL, Fujinaga T, Ikeda M, Shoji T, Katakura H, Motoyama H, Menju T, Aoyama A, Sato T, Chen-Yoshikawa TF, Sonobe M, Date H
Interact Cardiovasc Thorac Surg 2019 Mar 1;28(3):375-379. doi: 10.1093/icvts/ivy260. PMID: 30137401
Adrenocorticotropic hormone-producing thymic neuroendocrine carcinoma with oncocytic features: a case report and review of literature.
Falk NK, Weissferdt A, Habra MA, Roy-Chowdhuri S
Diagn Cytopathol 2015 Apr;43(4):329-34. Epub 2014 Oct 30 doi: 10.1002/dc.23209. PMID: 25354884
Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.
Weissferdt A, Tang X, Wistuba II, Moran CA
Mod Pathol 2013 Dec;26(12):1554-60. Epub 2013 Jun 21 doi: 10.1038/modpathol.2013.111. PMID: 23787439

Clinical prediction guides

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN
JCO Precis Oncol 2024 Nov;8:e2400328. Epub 2024 Nov 7 doi: 10.1200/PO.24.00328. PMID: 39509670
Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin: A comparative study with their pulmonary counterparts.
Bi Y, Deng Y, Li S, Zhou X, Chen Y, Ma D, Mao X, Guan Y, Chen J, Meng Y
J Surg Oncol 2016 Nov;114(6):697-702. Epub 2016 Oct 20 doi: 10.1002/jso.24393. PMID: 27761900
Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases.
Moran CA, Suster S
Am J Clin Pathol 2000 Jul;114(1):100-10. doi: 10.1309/3PDN-PMT5-EQTM-H0CD. PMID: 10884805
Neuroendocrine carcinoma of the thymus: aspiration biopsy, immunocytochemistry, and clinicopathologic correlates.
Gherardi G, Marveggio C, Placidi A
Diagn Cytopathol 1995 Mar;12(2):158-64. doi: 10.1002/dc.2840120216. PMID: 7774498

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2023
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...